Serum copeptin might improve risk stratification and management of aortic valve stenosis: a review of pathophysiological insights and practical implications

Basit Öğe Kaydı
dc.authoridyalta, kenan/0000-0001-5966-2488
dc.contributor.authorYalta, Kenan
dc.contributor.authorPalabiyik, Orkide
dc.contributor.authorGurdogan, Muhammet
dc.contributor.authorGurlertop, Yekta
dc.date.accessioned2024-06-12T10:52:15Z
dc.date.available2024-06-12T10:52:15Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractOver recent decades, the prevalence of aortic valve stenosis (AVS) has been constantly increasing possibly owing to the aging of general population. Severe AVS as determined by an aortic valve area (AVA) of <1 cm(2) has been regarded as a serious clinical condition potentially associated with a variety of adverse outcomes, including sudden cardiac death (SCD). However, patients with severe AVS (in the absence of overt high-risk features) are usually evaluated and managed exclusively based on symptomatology or imperfect prognostic tools including exercise testing and biomarkers, with a potential risk of mismanagement, suggesting the need for further objective risk stratifiers in this setting. Within this context, copeptin (C-terminal pro-vasopressin), a novel neurohormone widely considered as the surrogate marker of the arginine-vasopressin (AVP) system, may potentially serve as a reliable prognostic and therapeutic guide (e.g. timing of aortic valvular intervention) in patients with severe AVS largely based on its hemodynamic, fibrogenic as well as autonomic implications in these patients. Accordingly, the present paper aims to discuss clinical and pathophysiological implications of copeptin in the setting of AVS along with a summary of biomarkers and other prognostic tools used in this setting.en_US
dc.identifier.doi10.1177/1753944719826420
dc.identifier.endpage11en_US
dc.identifier.issn1753-9447
dc.identifier.issn1753-9455
dc.identifier.pmid30803406en_US
dc.identifier.scopus2-s2.0-85062191533en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1177/1753944719826420
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18648
dc.identifier.volume13en_US
dc.identifier.wosWOS:000662991500001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTherapeutic Advances In Cardiovascular Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAortic Valve Stenosisen_US
dc.subjectCopeptinen_US
dc.subjectPrognostic Implicationen_US
dc.subjectPrognostic Toolen_US
dc.subjectTherapeutic Implicationen_US
dc.subjectArginine-Vasopressin Increasesen_US
dc.subjectValvuloarterial Impedanceen_US
dc.subjectHeart-Failureen_US
dc.subjectBiomarkersen_US
dc.subjectProgressionen_US
dc.subjectExerciseen_US
dc.subjectPredictorsen_US
dc.subjectActivationen_US
dc.subjectSclerosisen_US
dc.subjectStatinsen_US
dc.titleSerum copeptin might improve risk stratification and management of aortic valve stenosis: a review of pathophysiological insights and practical implicationsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu